Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Upgrade: Dedicated Screeners for Stocks & ETFs

Inhibikase Therapeutics

Contributing Author

Recent Articles by Inhibikase Therapeutics

Oct-27	Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026 IKT GlobeNewswire
Oct-20	Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors IKT GlobeNewswire
Oct-02	Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IKT GlobeNewswire
Aug-11	Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity IKT GlobeNewswire
Jul-23	Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH IKT +7.37% GlobeNewswire
Jul-14	Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility IKT +5.10% GlobeNewswire
Jul-02	Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IKT GlobeNewswire
May-12	Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity IKT -5.42% GlobeNewswire
Apr-07	Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension IKT GlobeNewswire
Apr-03	Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IKT GlobeNewswire
Mar-26	Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity IKT GlobeNewswire
Nov-20	Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants IKT GlobeNewswire
Nov-20	Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants IKT GlobeNewswire
Nov-20	Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension IKT GlobeNewswire
Nov-14	Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity IKT GlobeNewswire
Aug-19	Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer IKT GlobeNewswire
Aug-14	Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity IKT GlobeNewswire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)